Simulations Plus Inc
NASDAQ:SLP

Watchlist Manager
Simulations Plus Inc Logo
Simulations Plus Inc
NASDAQ:SLP
Watchlist
Price: 28.33 USD -0.87% Market Closed
Market Cap: 568.6m USD
Have any thoughts about
Simulations Plus Inc?
Write Note

Simulations Plus Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Simulations Plus Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Simulations Plus Inc
NASDAQ:SLP
Revenue
$70m
CAGR 3-Years
15%
CAGR 5-Years
16%
CAGR 10-Years
20%
Veeva Systems Inc
NYSE:VEEV
Revenue
$2.7B
CAGR 3-Years
15%
CAGR 5-Years
21%
CAGR 10-Years
25%
Inspire Medical Systems Inc
NYSE:INSP
Revenue
$755.6m
CAGR 3-Years
55%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Revenue
$475.4m
CAGR 3-Years
32%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Revenue
$1.1B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
10%
W
Waystar Holding Corp
NASDAQ:WAY
Revenue
$791m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Simulations Plus Inc
Revenue Breakdown

Breakdown by Geography
Simulations Plus Inc

Total Revenue: 70m USD
100%
Americas: 50.5m USD
72.1%
EMEA: 14.1m USD
20.1%
Asia Pacific: 5.5m USD
7.8%

Breakdown by Segments
Simulations Plus Inc

Total Revenue: 70m USD
100%
Software: 41m USD
58.6%
Services: 29m USD
41.4%
Software Licenses: 956k USD
1.4%

Simulations Plus Inc
Glance View

Market Cap
568m USD
Industry
Health Care

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.

SLP Intrinsic Value
19.62 USD
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Simulations Plus Inc's Revenue?
Revenue
70m USD

Based on the financial report for Aug 31, 2024, Simulations Plus Inc's Revenue amounts to 70m USD.

What is Simulations Plus Inc's Revenue growth rate?
Revenue CAGR 10Y
20%

Over the last year, the Revenue growth was 18%. The average annual Revenue growth rates for Simulations Plus Inc have been 15% over the past three years , 16% over the past five years , and 20% over the past ten years .

Back to Top